BioCentury on BioBusiness,
Finance
Regulatory, clinical and other milestones
Highlights of weekly biotech stock moves
-- Andrew Fisher & Jon Wolleben
Published on
Monday, September 24, 2012
Regulatory
milestones
Amgen Inc. (NASDAQ:AMGN) gained $0.67 to $82.03 last week
after FDA approved an sBLA for Prolia denosumab to increase bone mass
in men with osteoporosis at high risk for fracture. Prolia is already approved
in the U.S. and EU to treat osteoporosis in postmenopausal women and in the EU
to treat bone loss associated with hormone ablation in men with prostate
cancer. The product is approved in the U.S. and EU as Xgeva to prevent skeletal
related events in adults with bone metastases from solid tumors.
85
words displayed of
1370
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]